Federal Lawsuit Challenges “Politically Manufactured” Marijuana Rescheduling Order
- 5 hours ago
- 4 min read
 May 29, 2026 Americans Against Legalizing Marijuana (AALM) has received notice of a federal lawsuit challenging one of the most haphazard and legally indefensible drug-policy actions in modern American history: the Biden-Trump Administration’s effort to move marijuana from Schedule I to Schedule III under the Controlled Substances Act. The plaintiffs in the lawsuit include a cannabis addiction recovery clinic, two doctors, a cannabis industry victims rights organization and a cannabinoid medical company. The lawsuit claims that Acting Attorney General Todd Blanche’s April 22 order attempts to federally legitimize state "medical" marijuana systems without requiring the scientific scrutiny, FDA approval, medical safeguards, or regulatory accountability demanded of every other federally recognized medicine. According to AALM, the order represents not reform, but political capitulation to a powerful and rapidly expanding marijuana industry whose profits depend on normalizing high-potency THC consumption while minimizing its risks.“This administration is trying to declare marijuana medicine by political decree instead of scientific proof,” said AALM President Carla Lowe. “If this order stands, it will fundamentally corrupt the integrity of the FDA approval process and the Controlled Substances Act itself.” "The lawsuit names President Trump as a defendant because it was his Executive Order that started this arbitrary process" stated David Evans Chief Counsel for the Cannabis Industry Victims Educating Litigators (CIVEL). Federal Government Accused of Creating a Fraudulent Medical System The lawsuit centers on the allegation that the federal government is creating a legally unprecedented “hybrid” drug category that exempts marijuana from standards applied to every other Schedule III controlled substance.Under federal law, Schedule III drugs require: 1. FDA-reviewed safety and efficacy data 2. Physician oversight 3. Controlled prescribing systems 4. Manufacturing controls 5. Pharmacy accountability 6. Labeling and warning requirements 7. Standardized dosing State "Medical" Marijuana satisfies none of those requirements. Yet the Attorney General’s order would permit state medical marijuana products — including raw cannabis flower, ultra-high potency THC concentrates, vape oils, edibles and THC products exceeding 90% potency, to bypass the safeguards imposed on every other federally recognized controlled medicine. This creates a dangerous double standard where political favoritism replaces evidence-based medicine. “Medical Marijuana” Without Medical Standards AALM claims the term “medical marijuana” itself has become politically weaponized and scientifically hollow. Unlike legitimate medicines, state "medical" marijuana marijuana has:
State "medical" marijuana programs operate largely through subjective physician “recommendations” rather than actual prescriptions. In most jurisdictions, patients can obtain marijuana approvals with little or no meaningful medical evaluation. AALM argues that these systems bear virtually no resemblance to federally regulated medical frameworks and instead function as commercial retail operations masquerading as healthcare.
“Calling something medicine does not make it medicine,” says AALM VP Scott Chipman. “Medicine requires science, standardization, clinical evidence, and accountability. The marijuana industry has spent years bypassing those requirements while demanding the credibility of pharmaceutical legitimacy.” FDA Approval Process Being Circumvented
The lawsuit further argues that the Department of Justice is attempting to use United Nations rescheduling powers to circumvent our federal Food, Drug, and Cosmetic Act entirely.
While the FDA has approved isolated synthetic THC cannabinoid-based pharmaceuticals it has never approved smoked or raw plant derived marijuana containing THC as safe or effective medicine. According to the complaint, this political shortcut undermines decades of public-health protections and creates a dangerous precedent in which public pressure and industry lobbying override scientific review. Public Health Risks Ignored
The lawsuit will also accuse federal officials of not providing physicians with FDA-quality evidence documenting marijuana-related harms, including:
In addition, the lawsuit will highlight hundreds of known harmful marijuana interactions involving medications such as warfarin, benzodiazepines, antiepileptic drugs, sedatives, statins, corticosteroids, and psychiatric medications.
AALM claims that no comprehensive federal physician informational framework exists to safely manage these interactions. “The first obligation of medicine is ‘do no harm,’” added VP Scott Chipman. “This rescheduling effort abandons that principle in favor of politics, ideology, and corporate profit.”
Lawsuit Challenges Legality of Order
The lawsuit raises multiple legal challenges, including whether the Attorney General:
“This case is about far more than marijuana,” stated Evans. "It is about whether science and the rule of law still matter in American drug policy.”
Media Contacts:Carla Lowe, President, AALM(916) 708-4111carladlowe@aol.comScott Chipman, Vice President, AALM(619) 990-7480scott@chipman.infoDave Evans, Chief Legal Counsel Cannabis Industry Victims Educating Litigators (CIVEL)(908) 963-0254seniorcounsel@civel.orgPatrick Kenneally, Esq.Connor Mighell, Esq.Burke Law Group(847) 651-8525Dr. Ken Finn, Plaintiff(719) 331-9199 Dr. Libby Stuyt, Plaintiff(719) 671-1611
|
We appreciate your generous donation! Petition for Review Circuit Court of Appeals District of Columbia New Directions V. Trump |
Comments